Current Urology Reports

, Volume 14, Issue 3, pp 192–198

Risk-Based Prostate Cancer Screening: Who and How?

  • Allison S. Glass
  • K. Clint Cary
  • Matthew R. Cooperberg
Prostate Cancer (D Parekh, Section Editor)

DOI: 10.1007/s11934-013-0319-8

Cite this article as:
Glass, A.S., Cary, K.C. & Cooperberg, M.R. Curr Urol Rep (2013) 14: 192. doi:10.1007/s11934-013-0319-8

Abstract

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

Keywords

Prostate cancerScreening toolsProstate-specific antigenRisk-basedClinical risk

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Allison S. Glass
    • 1
  • K. Clint Cary
    • 1
  • Matthew R. Cooperberg
    • 1
  1. 1.Department of UrologyUniversity of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoUSA